Liver metastases

Tsilimigras, Diamantis I.; Brodt, Pnina; Clavien, Pierre‐Alain; Muschel, Ruth J.; D’Angelica, Michael I.; Endo, Itaru; Parks, Rowan W.; Doyle, Majella B.; Santibañés, Eduardo de; Pawlik, Timothy M.

doi:10.1038/s41572-021-00261-6

Cited by 260 publications

(237 citation statements)

References 282 publications

Supporting

Mentioning

204

Contrasting

Order By: Relevance

“…Histological examinations including morphological and IHC analyses are the gold standard for tumor origin diagnosis. However, most of the LM originated from adenocarcinoma, which shares overlapping histological features with primary liver tumors or between each other (1). Thus, additional The degree of differentiation of 49 specimens was undefined.…”

Section: Discussionmentioning

confidence: 99%

“…Liver metastases (LM) are tumors that have propagated to the liver from tumors originating from other parts of the body. Due to the venous blood returning from the gastrointestinal system through portal vein circulation, gastrointestinal tract tumors are more likely to metastasize to the liver (1). Besides, the liver microenvironment also plays a significant role in the development of hepatic metastasis.…”

Section: Introductionmentioning

confidence: 99%

“…According to the statistical data in the Surveillance, Epidemiology and End Results (SEER) database, 5.14% to 6.46% of cancer patients are diagnosed with synchronal LM at the time of primary cancer diagnosis (3,4). Of note, during the course of the cancer disease, up to 50% of patients with various tumor types will either present with or develop LM (1). The most common tumor that spreads to the liver is breast cancer for younger women and colorectal cancers for younger men (3).…”

Section: Introductionmentioning

confidence: 99%

“…Traditionally, the treatment approaches were established according to the primary tumor of LM. For example, resection can be usually performed in patients with colorectal liver metastases (CLM) and neuroendocrine tumor liver metastases (NETLM), but it may be not appropriate for patients with LM from pancreatic cancer, esophageal cancer, melanoma and adrenocortical cancer (1). In addition, different tumor types carry specific genetic alterations, genomic feature analysis which could provide precise and pertinent clinical details for disease management.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Gene Expression Profiling for Differential Diagnosis of Liver Metastases: A Multicenter, Retrospective Cohort Study

Wang

Jiang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundLiver metastases (LM) are the most common tumors encountered in the liver and continue to be a significant cause of morbidity and mortality. Identification of the primary tumor of any LM is crucial for the implementation of effective and tailored treatment approaches, which still represents a difficult problem in clinical practice.MethodsThe resection or biopsy specimens and associated clinicopathologic data were archived from seven independent centers between January 2017 and December 2020. The primary tumor sites of liver tumors were verified through evaluation of available medical records, pathological and imaging information. The performance of a 90-gene expression assay for the determination of the site of tumor origin was assessed.ResultA total of 130 LM covering 15 tumor types and 16 primary liver tumor specimens that met all quality control criteria were analyzed by the 90-gene expression assay. Among 130 LM cases, tumors were most frequently located in the colorectum, ovary and breast. Overall, the analysis of the 90-gene signature showed 93.1% and 100% agreement rates with the reference diagnosis in LM and primary liver tumor, respectively. For the common primary tumor types, the concordance rate was 100%, 95.7%, 100%, 93.8%, 87.5% for classifying the LM from the ovary, colorectum, breast, neuroendocrine, and pancreas, respectively.ConclusionThe overall accuracy of 93.8% demonstrates encouraging performance of the 90-gene expression assay in identifying the primary sites of liver tumors. Future incorporation of the 90-gene expression assay in clinical diagnosis will aid oncologists in applying precise treatments, leading to improved care and outcomes for LM patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Gene Expression Profiling for Differential Diagnosis of Liver Metastases: A Multicenter, Retrospective Cohort Study

Wang

Jiang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Intense structural remodeling of the ECM through the release of MMPs, periostin, tenascin-C, and osteopontin is crucial in cholangiocarcinogenesis, as described above [ 7 ]. Indeed, the overexpression of matricellular proteins has been related to tumor growth, lymph node metastatic potential, and poor OS [ 120 , 121 ]. Elevated expression of osteopontin in stromal cells, in particular, has been significantly correlated with tumor size, local and distant invasion, and advanced stage, through the activation of RAS-RAF-MEK-ERK and Wnt/β-caterin signaling pathways, in BTC patients [ 122 , 123 ].…”

Section: Immunological Characterisation Of Iccmentioning

confidence: 99%

The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma

Fiste

Ntanasis‐Stathopoulos

Gavriatopoulou

et al. 2021

Vaccines

View full text Add to dashboard Cite

Biliary tract cancer, and intrahepatic cholangiocarcinoma (iCC) in particular, represents a rather uncommon, highly aggressive malignancy with unfavorable prognosis. Therapeutic options remain scarce, with platinum-based chemotherapy is being considered as the gold standard for the management of advanced disease. Comprehensive molecular profiling of tumor tissue biopsies, utilizing multi-omics approaches, enabled the identification of iCC’s intratumor heterogeneity and paved the way for the introduction of novel targeted therapies under the scope of precision medicine. Yet, the unmet need for optimal care of patients with chemo-refractory disease or without targetable mutations still exists. Immunotherapy has provided a paradigm shift in cancer care over the past decade. Currently, immunotherapeutic strategies for the management of iCC are under intense research. Intrinsic factors of the tumor, including programmed death-ligand 1 (PD-L1) expression and mismatch repair (MMR) status, are simply the tip of the proverbial iceberg with regard to resistance to immunotherapy. Acknowledging the significance of the tumor microenvironment (TME) in both cancer growth and drug response, we broadly discuss about its diverse immune components. We further review the emerging role of immunotherapy in this rare disease, summarizing the results of completed and ongoing phase I–III clinical trials, expounding current challenges and future directions.

show abstract

Bioprinting of Perfusable Vascularized Organ Models for Drug Development via Sacrificial‐Free Direct Ink Writing

Wu,

Pang,

Berg

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

Abstract3D bioprinting enables the fabrication of human organ models that can be used for various fields of biomedical research, including oncology and infection biology. An important challenge, however, remains the generation of vascularized, perfusable 3D models that closely simulate natural physiology. Here, a novel direct ink writing (DIW) approach is described that can produce vascularized organ models without using sacrificial materials during fabrication. The high resolution of the method allows the one‐step generation of various sophisticated hollow geometries. This sacrificial‐free DIW (SF‐DIW) approach is used to fabricate hepatic metastasis models of various cancer types and different formats for investigating the cytostatic activity of anti‐cancer drugs. To this end, the models are incorporated into a newly developed perfusion system with integrated micropumps and an agar casting step that improves the physiological features of the bioprinted tissues. It is shown that the hepatic environment of the tumor models is capable of activating a prodrug, which inhibits breast cancer growth. This versatile SF‐DIW approach is able to fabricate complicated perfusable constructs or microfluidic chips in a straightforward and cost‐efficient manner. It can also be easily adapted to other cell types for generating vascularized organ tissues or cancer models that may support the development of new therapeutics.

show abstract

Liver metastases

Cited by 260 publications

References 282 publications

Gene Expression Profiling for Differential Diagnosis of Liver Metastases: A Multicenter, Retrospective Cohort Study

Gene Expression Profiling for Differential Diagnosis of Liver Metastases: A Multicenter, Retrospective Cohort Study

The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma

Bioprinting of Perfusable Vascularized Organ Models for Drug Development via Sacrificial‐Free Direct Ink Writing

Contact Info

Product

Resources

About